Preparation and application of fusion protein for treating hypercholesteremia

The invention discloses a PCSK9-combined fusion protein which is represented by the following general formula: X-connecting peptide-Y-connecting peptide-Z-connecting peptide-IgG Fc segment, wherein X, Y and Z are EGF(A) region polypeptide mutants in LDL-R (low-density lipoprotein receptor), and the...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	LUO DIXIANG, LI SHENGWEI, FU WEI, GAO XIAOPING, DAI YANPING, CHENG LIN
Format:	Patent
Sprache:	eng
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The invention discloses a PCSK9-combined fusion protein which is represented by the following general formula: X-connecting peptide-Y-connecting peptide-Z-connecting peptide-IgG Fc segment, wherein X, Y and Z are EGF(A) region polypeptide mutants in LDL-R (low-density lipoprotein receptor), and the connecting peptide is (GGGGS)n. The fusion protein disclosed by the invention can be combined with the PCSK9 at high affinity to inhibit the PCSK9 from degrading the hepatocyte LDL-R and increase the intake of the hepatocytes for LDL-C, and thus, has obvious advantages and favorable prospects in the aspect of treating hypercholesteremia, familial hypercholesteremia and other diseases.